Frank Wellborne is a Rheumatology/Immunology physician affiliated with Houston Institute for Clinical Research. OpenAlex indexes 7 publications with 971 citations (h-index 5).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
901 B Tx 337 Loop
New Braunfels, TX 78130
Telephone
713-995-9465Provider last certified this registry record 25 Apr 2022.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year202541 payments$37,232openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202537 payments$35,118openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year202525 payments$15,148openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
56%Corticosteroid56%Prednisone100%Part D<11 patientsCancer & immunology
44%Folate Analog Metabolic Inhibitor44%Methotrexate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- SAT0127 The efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index
Annals of the Rheumatic Diseases
2018 - Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
Annals of the Rheumatic Diseases
2008
Similar KOLs
Other experts from the same institution or the same specialty.
Frank Lanza, MD
Houston Institute for Clinical Research
Suzanne Bruce, MD
Houston Institute for Clinical Research
Daniel Carrasco, MD
Houston Institute for Clinical Research
Cindy Berthelot, MD
Houston Institute for Clinical Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”